drugset / Trial / NCT03243331
An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer
NaSequentialOpen-labelTreatment
Summary
Phase 1 study to evaluate the safety and effect of Gedatolisib and PTK7-ADC for the treatment of triple negative breast cancer
Timeline
- Start
- 2018-01-19
- Primary completion
- 2020-05-27
- Completion
- 2020-05-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gedatolisib | Small molecule | 110 mg | Intravenous |
| Subject | Gedatolisib | Small molecule | 180 mg | Intravenous |
| Subject | PTK7-ADC | Unknown | 1.4 mg/kg | — |
| Subject | PTK7-ADC | Unknown | 2.8 mg/kg | — |